The gross margin expansion from 37.8% to 44.3% year-over-year indicates that Ingevity is successfully managing CTO input costs or passing through price increases, as COGS declined faster than revenue. However, the operating margin of 19.1% in Q2 2026, while healthy, is below the 23.5% posted a year earlier, reflecting the impact of lower volumes on fixed-cost absorption. The negative net margins in prior quarters were driven by large non-cash impairments, as evidenced by the gap between operating and net income; investors should focus on adjusted operating metrics to gauge true earning power.

ROIC of 3.8% in Q2 2026 is modest but consistent with the 3-4% range seen over the past two years, indicating that the company is not destroying value on its invested capital, but also not compounding returns. The stability in ROIC, despite revenue contraction, implies that management has been effective in reducing the asset base through divestitures or impairments, aligning capital with lower demand. However, ROE has been extremely volatile, swinging from -100.8% to 174.3% in recent quarters, which is a direct consequence of the shrinking equity base; this makes ROE an unreliable measure of performance for Ingevity.

Inventory days on hand have remained stubbornly high, averaging over 100 days in the past year, which is consistent with a high fixed-cost manufacturing business that must maintain production continuity. The slight improvement in DSO to 44 days from 45 days indicates disciplined receivables management, but the overall CCC of 92 days is still elevated compared to the 104 days seen in Q2 2024. This suggests that working capital efficiency has not materially improved despite the revenue contraction, and the negative free cash flow margin of -7.7% in Q2 2026 highlights the cash drag from inventory buildup.

The near-total write-off of goodwill, from $525.9 million to $4.3 million, has artificially depressed equity, making the D/E ratio appear dangerously high. However, the absolute debt level has been stable, and interest coverage of 3.89x in Q2 2026, while improved from negative levels in prior quarters, remains thin relative to the cyclicality of earnings. Investors should monitor the company's ability to refinance its debt given the strained equity base and the potential for further impairments, but the underlying operational leverage is less severe than the ratio suggests.

The improvement in the current ratio is driven by a reduction in current liabilities, likely from paydown of short-term debt, rather than a buildup of cash. However, the cash balance of $97.4 million is modest relative to the $1.2 billion in total debt, and the negative operating cash flow in Q2 2026 suggests that the company may need to rely on external financing or asset sales to fund its obligations. The quick ratio of 1.15 provides some comfort, but in a severe downturn, the company's ability to generate cash from inventory may be limited given the specialized nature of its products.